8-K - Envoy Medical, Inc. (0001840877) (Filer)

424B5 - Envoy Medical, Inc. (0001840877) (Filer)

424B5 - Envoy Medical, Inc. (0001840877) (Filer)

8-K - Envoy Medical, Inc. (0001840877) (Filer)

8-K - Envoy Medical, Inc. (0001840877) (Filer)

8-K - Envoy Medical, Inc. (0001840877) (Filer)

8-K - Envoy Medical, Inc. (0001840877) (Filer)

424B3 - Envoy Medical, Inc. (0001840877) (Filer)

EFFECT - Envoy Medical, Inc. (0001840877) (Filer)

POS AM - Envoy Medical, Inc. (0001840877) (Filer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

3 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

White Bear Lake, Minnesota--(Newsfile Corp. - September 25, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 1,908,402 shares of its Class A common stock at a purchase price of $1.31 per share of Class A common stock. In addition, in a concurrent private placement, Envoy Medical issued and sold unregistered warrants to purchase up to 5,725,206 shares of Class A common stock. The unregistered warrants have an exercise price of $1.31 per share of Class A common sto

The Company Begins Strategic Preparations To Support Anticipated Demand And Optimization Of The Acclaim® Fully Implanted Cochlear Implant OpportunitySix-month follow-up visits are now underway and will continue over the next two monthsWhite Bear Lake, Minnesota--(Newsfile Corp. - September 24, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced it is scaling its commercialization planning for the company's breakthrough investigational Acclaim® fully implanted hearing device, as its pivotal clinical trial continues to build momentum. The Company's proactive approach reflects

White Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,908,402 shares of its Class A common stock at a purchase price of $1.31 per share of Class A common stock, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Envoy Medical will issue and sell unregistered warrants to purchase up to 5,725,206 shares of Class A common stock. The unregistered warrants have an e

Patent covers advanced signal processing for middle ear sensors, further advancing the Company's position in leveraging the ear for fully implanted hearing devicesWhite Bear Lake, Minnesota--(Newsfile Corp. - September 19, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that it has received an Issue Notification from the European Patent Office and has been granted European Patent No. 4338791 which became effective September 17, 2025. The newly issued European patent strengthens Envoy Medical's global patent portfolio following recent issuances in the United States, Austr

Highlights include Expanded Global Patent Portfolio, Complete Debt Elimination Strengthening Balance Sheet, and Further Momentum of Pivotal Clinical TrialWhite Bear Lake, Minnesota--(Newsfile Corp. - September 10, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted technologies, today issued a letter to shareholders commenting on recent accomplishments and other operational updates from Chief Executive Officer, Brent Lucas.Dear Shareholders:The third quarter of 2025 has been one of tremendous progress and momentum for Envoy Medical. As "America's Hearing Implant Company," we are proud to be redefining what is

Patents strengthen Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss.White Bear Lake, Minnesota--(Newsfile Corp. - September 9, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of four new global patents. These patents expand the company's global intellectual property portfolio and mark another strategic step in delivering next-generation cochlear implant solutions that offer patients discreet, 24/7 hearing experience without the limitation of externally worn components. The fol

White Bear Lake, Minnesota--(Newsfile Corp. - September 8, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025 in New York City.Mr. Lucas' presentation is now available on demand in the Investor Relations section of the Envoy Medical's website at https://ir.envoymedical.com/news-events/ir-calendar. You may also view the presentation via this link: https://journey.ct.events/v

No Serious Adverse Events or Unanticipated Device Effects Reported; Company Confirms Program Remains On TrackWhite Bear Lake, Minnesota--(Newsfile Corp. - September 3, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted technologies, today announced that the patients in the first stage of its pivotal clinical trial for the investigational Acclaim® fully implanted cochlear implant have successfully reached their three-month follow-up milestone. During this timeframe, no serious adverse events (SAEs) or unanticipated device effects (UADEs) were reported.Envoy Medical's pivotal trial is designed to evaluate the

Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversionWhite Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, who also announced his retirement from the Envoy Medical board after two decades of ser

Patents issued in the U.S., Australia, and Hong Kong advance Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss.White Bear Lake, Minnesota--(Newsfile Corp. - August 20, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents across the United States, Australia, and Hong Kong. These patents expand the company's global intellectual property portfolio and mark another strategic step in delivering next-generation cochlear implant solutions that offer patients discreet,

White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events.Financial and Corporate Highlights for Second Quarter and to date:Strong momentum continues in the pivotal clinical trial of its investigational novel hearing device, the fully implanted Acclaim® cochlear implant.Successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. A

Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat

Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to

WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous

Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year WHITE BEAR LAKE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the second quarter ended June 30, 2024. "We are pleased with the steady progress that Envoy Medical has made this quarter and year-to-date in advancing our goal of becoming a leading cochle

The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its "breakthrough" fully implanted cochlear implant. WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the first quarter ended March 31, 2024. Financial and Corporate Highlights from Q1 2024 All three participants in the ongoing Early Feasibility Study (EFS) at Mayo Clinic (Rochester, MN) have completed their 12-m

Company Provides Corporate Update that Include Updates on its Investigational Fully Implanted Acclaim® Cochlear Implant Meeting its Early Feasibility Study Milestones Recent bipartisan Congressional bill, the Hearing Device Coverage Clarification Act, seeks to open a pathway to insurance coverage for the Company's Esteem® Fully Implanted Active Middle Ear Implant WHITE BEAR LAKE, Minn., April 02, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2023. Financial and

Interim Findings from Early Feasibility Trial Provide Important Learnings and Feedback Ahead of Pivotal Clinical Trial Planned for 2024 Virtual Fireside Chat to be held December 7 WHITE BEAR LAKE, Minn., Nov. 20, 2023 (GLOBE NEWSWIRE) --  Envoy Medical, Inc. ("Envoy Medical") (NASDAQ:COCH), a hearing health company, today is providing a business update and its financial results for the quarter ended September 30, 2023. The Company will host a virtual fireside chat event on December 7, which will cover a range of topics, including introductions to the technology, financial and clinical aspects of the business, as well as potential participation from cochlear implant key opinion leader

SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversionWhite Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, who also announced his retirement from the Envoy Medical board after two decades of ser

WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently

Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company